Newly engineered gold based molecules look to be safer and more effective at fighting cancer than prominent platinum based therapies. It is especially effective at halting testicular cancer, with a success rate of more than 90%. Now, a study by RMIT University in Melbourne, Australia — the results of which appear in Chemistry: A European Journal — has announced the engineering of four gold based, bioactive molecules for use in cancer treatment. Preclinical trials have shown these molecules to be up to 24 times as effective as cisplatin at killing some cancer cells. They are also better at arresting tumor growth, and they are resistant to other medications, allowing them to remain effective for longer. "Our results show there's incredible potential here for the development of new cancer fighting therapeutics that can deliver lasting power and precision." Says study co-author Neda Mirzadeh. The Molecular Engineering Group is now looking to acquire funding for its next steps: human clinical studies and regulatory approval. (Credits: www.medicalnewstoday.com)
